Bavarian Nordic and CEPI partner to advance Mpox vaccination in Africa

https://cepi.net/bavarian-nordic-and-cepi-partner-advance-mpox-vaccination-africa?utm_campaign=morning_rounds&utm_medium=email&_hsenc=p2ANqtz-9SVSeP-TfsthPx7greS7SI17IICP_FjsGqqxb9L9eXFBC_QsR1JfthYITb51YA4MgdVuv7dwSjLyHCXGv3LWSjfRLF4A&_hsmi=317667934&utm_content=317667934&utm_source=hs_email Mpox vaccine trial to start in three African countries Researchers from McMaster University in Canada are planning a clinical trial to test whether receiving Bavarian Nordic’s mpox vaccine can protect people who’ve been exposed to the infection from getting sick or reduce the severity of the illness. The trial will launch next month in the Democratic Republic of Congo and will later include participants in Uganda and Nigeria. The researchers received $4.9 million (U.S.) from the Coalition for Epidemic Preparedness Innovations and the Canadian Institutes of Health Research, per a CEPI press release. The trial’s results could be critical to combat mpox in the DRC, which has seen 11,000 cases and 443 deaths this year already, with children making up the majority of both, the press release noted. The study will invite over 1500 participants over the age of 10 from households with a confirmed mpox infection to participate. CEPI and Bavarian Nordic also have a separate clinical trial that will launch later in the year testing the mpox vaccine in children ages 2-12. Mpox Our latest coverage of the unprecedented mpox outbreak spreading across multiple continents. https://www.statnews.com/topic/mpox/?utm_campaign=morning_rounds&utm_medium=email&_hsenc=p2ANqtz-9X2KAp2V9OjqRVt3V-3wIKAvJn2-uPT6YxDQQ9IAMc_tB657zuOefe46qPuGombDzj8-btEKr4IYrsGSaNK2Hz7rs3tQ&_hsmi=317667934&utm_content=317667934&utm_source=hs_email